SCHEMBL1783360

SCHEMBL1783360

CC(C)CCCC(O)CC=O

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.39
BLM P54132 1/20 0.38
PTPN1 P18031 2/20 0.33
MEN1 O00255 1/20 0.33
CYP3A4 P08684 1/20 0.33
ALOX15 P16050 1/20 0.33
KMT2A Q03164 1/20 0.33
FFAR1 O14842 1/20 0.31
FFAR4 Q5NUL3 1/20 0.31
KDM4C Q9H3R0 2/20 0.31
KDM4A O75164 1/20 0.31
PHF8 Q9UPP1 1/20 0.31
KDM2A Q9Y2K7 1/20 0.31
KDM1A O60341 1/20 0.30
CA1 P00915 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1783444 0.95 LMNA (0.39) LMNABLMFFAR1FFAR4KDM4C
SCHEMBL8181768 0.93 LMNA (0.37) LMNABLMFFAR1FFAR4KDM4C
SCHEMBL27215948 0.93 LMNA (0.37) LMNABLMFFAR1FFAR4KDM4C
SCHEMBL1784320 0.93 LMNA (0.37) LMNABLMFFAR1FFAR4KDM4C
SCHEMBL1781193 0.86 CA1 (0.32) CA1
SCHEMBL1784280 0.83
SCHEMBL1781869 0.81 FFAR1 (0.32) LMNABLMFFAR1FFAR4
SCHEMBL1785933 0.79 TRPA1 (0.35) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL1783895 0.79 TSHR (0.37) LMNABLMPTPN1MEN1CYP3A4
SCHEMBL1785931 0.79 TRPA1 (0.35) LMNABLMPTPN1MEN1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2578597-B1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME GENOME PHARMACEUTICALS INST CO LTD (JP) 2015-07-15 EP claimed
US-8754040-B2 Cyclic peptide compound, method for producing same, anti-infective agent, antibiotic-containing fraction, antibiotic, method for producing antibiotic, antibiotic-producing microorganism, and antibiotic produced by same GENOME PHARMACEUTICALS INSTITUTE CO., LTD. (JP) 2014-06-17 US claimed
US-20130203654-A1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME THE UNIVERSITY OF TOKYO (JP) 2013-08-08 US claimed
EP-2578597-A1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME Genome Pharmaceuticals Institute Co., Ltd. (JP) 2013-04-10 EP claimed
EP-2578597-B1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME GENOME PHARMACEUTICALS INST CO LTD (JP) 2015-07-15 EP disclosed
US-8754040-B2 Cyclic peptide compound, method for producing same, anti-infective agent, antibiotic-containing fraction, antibiotic, method for producing antibiotic, antibiotic-producing microorganism, and antibiotic produced by same GENOME PHARMACEUTICALS INSTITUTE CO., LTD. (JP) 2014-06-17 US disclosed
US-8632792-B2 Cooling sensation agent composition and sensory stimulation agent composition TAKASAGO INTERNATIONAL CORPORATION (JP) 2014-01-21 US disclosed
US-20130203654-A1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME THE UNIVERSITY OF TOKYO (JP) 2013-08-08 US disclosed
EP-2578597-A1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME Genome Pharmaceuticals Institute Co., Ltd. (JP) 2013-04-10 EP disclosed
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2011-05-19 US disclosed
WO-2009123355-A2 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TAKASAGO INTERNATIONAL CORPORATION (JP) 2009-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110117147-A1 COOLING SENSATION AGENT COMPOSITION AND SENSORY STIMULATION AGENT COMPOSITION TRPA1, HRH1, HRH2 LMNA 1708/4885BLM 4418/4885PTPN1 4528/4885
US-20130203654-A1 NOVEL CYCLIC PEPTIDE COMPOUND, METHOD FOR PRODUCING SAME, ANTI-INFECTIVE AGENT, ANTIBIOTIC-CONTAINING FRACTION, ANTIBIOTIC, METHOD FOR PRODUCING ANTIBIOTIC, ANTIBIOTIC-PRODUCING MICROORGANISM, AND ANTIBIOTIC PRODUCED BY SAME MRPL21, NRDC, BPTF LMNA 4519/4885BLM 4384/4885PTPN1 1354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.